May 10 was a bad day for small companies trying to make it big with abuse deterrent opioid formulations.
The day began with Pain Therapeutics Inc. and Durect Corp. releasing copies of a letter they had received...
Pfizer’s acquisition of King gave the company a chance to play in a new kind of market: abuse deterrent opioid pain relief formulations. Two years later, Pfizer is moving in the other direction, even as FDA’s actions validate the notion that there is an opportunity—and that the scale of Big Pharma can play a critical role.
May 10 was a bad day for small companies trying to make it big with abuse deterrent opioid formulations.
The day began with Pain Therapeutics Inc. and Durect Corp. releasing copies of a letter they had received...
A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.
Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.
At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.